PACS Group Inc header image

PACS Group Inc

PACS

Equity

ISIN null / Valor 133777092

New York Stock Exchange, Inc (2025-11-17)
USD 15.70+48.4%

PACS Group Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

PACS Group, Inc. (PACS) is a holding company that has significantly expanded its footprint in the healthcare sector, specifically focusing on the post-acute care industry since its inception in 2013. Starting with just two skilled nursing facilities, PACS has grown into a substantial network, now encompassing over 200 facilities across nine states. The company's growth strategy involves investing in post-acute care facilities, healthcare professionals, and ancillary services to provide comprehensive care. PACS emphasizes a model that combines the benefits of a national support network with the autonomy of local decision-making in its operations. As of now, PACS and its affiliates manage 218 facilities, employing over 32,000 staff members, and cater to the daily needs of more than 20,000 patients and residents. This expansion reflects PACS's commitment to delivering mission-driven care and addressing the growing demand for post-acute healthcare services in the United States.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (05.10.2025):

PACS Group Inc. reported its second quarter of 2024 with significant revenue growth and expanded operations, despite a net loss influenced by stock-based compensation expenses related to its recent initial public offering. The company continues to enhance its portfolio and maintain strong occupancy rates across its healthcare facilities.

Revenue Growth

Consolidated GAAP revenue for the second quarter of 2024 reached $981.8 million, marking a 29% increase compared to the same quarter in 2023 and a 5% rise from the first quarter of 2024. This growth was primarily driven by an increase in facility count and higher reimbursement rates.

Net Income

The GAAP net income for the second quarter of 2024 was a loss of $10.9 million. This loss was largely due to a $90.9 million increase in stock-based compensation expense associated with restricted stock units granted during the company’s April 2024 initial public offering.

Adjusted EBITDA

Adjusted EBITDA for the second quarter of 2024 was $99.7 million. For the first six months of 2024, Adjusted EBITDA totaled $188.2 million, while Adjusted EBITDAR reached $165.6 million in the same quarter.

Full Year 2024 Guidance

PACS Group Inc. has increased its guidance for the full year 2024, projecting revenue between $3.85 billion and $3.95 billion and Adjusted EBITDA in the range of $370 million to $380 million.

Operational Highlights

During the second quarter of 2024, PACS added two operating facilities, including 167 skilled nursing beds. The total facilities occupancy stood at 91.0%, with ramping and mature facilities occupancy increasing by 1.4% and 1.0% respectively compared to the prior year.

Rate Increases

Average Medicare and Medicaid daily rates saw significant increases of 9.5% and 3.5% respectively in the second quarter of 2024 compared to the same quarter last year.

Expansion and Acquisitions

Over the twelve months ending June 30, 2024, PACS added 32 facilities and completed 12 real estate acquisitions. The company has expanded to a total of 248 operated facilities and 87 properties owned wholly or through joint venture partnerships.

Summarized from source with an LLMView Source

Key figures

-9.82%1Y
%3Y
%5Y

Performance

88.8%1Y
76.6%3Y
76.6%5Y

Volatility

Market cap

1731 M

Market cap (USD)

Daily traded volume (Shares)

11,860,420

Daily traded volume (Shares)

1 day high/low

12.93 / 12.55

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Bio-Rad Laboratories, Inc. Class B
Bio-Rad Laboratories, Inc. Class B Bio-Rad Laboratories, Inc. Class B Valor: 912794
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.18%USD 310.70
Helen of Troy Ltd
Helen of Troy Ltd Helen of Troy Ltd Valor: 938381
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.14%USD 17.55
Globus Medical Inc
Globus Medical Inc Globus Medical Inc Valor: 18329123
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.96%USD 83.64
Alkermes PLC
Alkermes PLC Alkermes PLC Valor: 13920929
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.00%USD 29.33
STERIS PLC
STERIS PLC STERIS PLC Valor: 47027903
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.54%USD 257.01
Unitedhealth Group Inc
Unitedhealth Group Inc Unitedhealth Group Inc Valor: 1078451
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.42%USD 320.52
Novo Nordisk A/S
Novo Nordisk A/S Novo Nordisk A/S Valor: 461641
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.41%USD 48.46
Perrigo Company PLC
Perrigo Company PLC Perrigo Company PLC Valor: 22008864
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.60%USD 13.56
Evolent Health Inc
Evolent Health Inc Evolent Health Inc Valor: 28153126
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-7.42%USD 3.87
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.08%USD 25.08